Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Renal Cell Carcinoma (RCC) Prognosis Panel

This comprehensive calculator evaluates prognosis for metastatic Renal Cell Carcinoma (mRCC) using both the modern IMDC (Heng) criteria and the historical MSKCC (Motzer) criteria.

Evidence-based context for fast calculator use

Purpose:
Combined IMDC (Heng) and MSKCC (Motzer) risk stratification for metastatic RCC.
Population:
patients whose clinical question requires the component models displayed in the combined panel
Factors:
Karnofsky Performance Status< 80%?, Time from Initial Diagnosis to Systemic Treatment < 1 year?, Hemoglobin < Lower Limit of Normal?, Corrected Calcium > Upper Limit of Normal?, Neutrophils > Upper Limit of Normal?, Platelets > Upper Limit of Normal?, LDH > 1.5x Upper Limit of Normal?
Reference:
Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799.
HomeRenal Cell Carcinoma (RCC) Prognosis Panel
Pin your most used calculators here by clicking the star in the dropdown.

Renal Cell Carcinoma (RCC) Prognosis Panel

Clinical Context & Background

This comprehensive calculator evaluates prognosis for metastatic Renal Cell Carcinoma (mRCC) using both the modern IMDC (Heng) criteria and the historical MSKCC (Motzer) criteria.
Clinical Guideline Note:
The IMDC (Heng) model is the current standard of care for risk stratification in the era of targeted therapy and immunotherapy (e.g., NCCN Guidelines). The MSKCC model is provided for historical context and comparison.
Shared Risk Factors (Both Models)
KPS < 80%: Karnofsky Performance Status less than 80%.
Time to Treatment < 1 year: Less than one year from initial diagnosis to start of systemic therapy.
Anemia: Hemoglobin < Lower Limit of Normal (LLN).
Hypercalcemia: Corrected Calcium > Upper Limit of Normal (ULN).
IMDC (Heng) Specific Factors
Neutrophilia: Neutrophil count > Upper Limit of Normal (ULN).
Thrombocytosis: Platelet count > Upper Limit of Normal (ULN).
MSKCC (Motzer) Specific Factors
High LDH: Lactate Dehydrogenase > 1.5 x Upper Limit of Normal (ULN).
Note: Local laboratory reference ranges for LLN and ULN should always take precedence over typical values.
Primary Source EvidenceHeng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794-5799.
Formula Logic
IMDC: 0 (Fav), 1-2 (Int), ≥3 (Poor) based on 6 factors. MSKCC: 0 (Fav), 1-2 (Int), ≥3 (Poor) based on 5 factors.

Reference Data

SystemRisk GroupScoreMedian OS (Historical)
IMDC (Heng)Favorable0 factors43.2 months
IMDC (Heng)Intermediate1 - 2 factors22.5 months
IMDC (Heng)Poor≥ 3 factors7.8 months
------------
MSKCC (Motzer)Favorable0 factors30 months
MSKCC (Motzer)Intermediate1 - 2 factors14 months
MSKCC (Motzer)Poor≥ 3 factors5 months

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Renal Cell Carcinoma (RCC) Prognosis Panel when combined IMDC (Heng) and MSKCC (Motzer) risk stratification for metastatic RCC.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning IMDC (Heng) through MSKCC (Motzer).
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Review every component result separately; if models disagree, verify inputs and follow the more cautious disease-specific pathway rather than averaging scores.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • A panel improves comparison but does not make component models interchangeable or create a new validated composite score.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients whose clinical question requires the component models displayed in the combined panel

How to apply this result

For a representative case, verify Karnofsky Performance Status< 80%?, Time from Initial Diagnosis to Systemic Treatment < 1 year?, Hemoglobin < Lower Limit of Normal?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

Myeloma Master Panel (R2-ISS & Frailty)Febrile Neutropenia TriagePalliative Survival Prediction

Frequently Asked Questions

When should Renal Cell Carcinoma (RCC) Prognosis Panel be used?

Use it for patients whose clinical question requires the component models displayed in the combined panel when all required inputs and the intended clinical setting are confirmed.

Can Renal Cell Carcinoma (RCC) Prognosis Panel determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.